✦ LIBER ✦

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer

✍ Scribed by Greco, F. Anthony; Bonomi, Philip; Crawford, Jeffrey; Kelly, Karen; Oh, Yun; Halpern, Wendy; Lo, Larry; Gallant, Gilles; Klein, Jerry

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of mapatumumab, a fully h

✍ Trarbach, T; Moehler, M; Heinemann, V; Köhne, C-H; Przyborek, M; Schulz, C; Snel 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 318 KB

202 POSTER Mapatumumab, a fully human ag

✍ C.H. Mom; S. Sleijfer; J.A. Gietema; N.L. Fox; C. Piganeau; L. Lo; D.R.A. Uges; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 60 KB

197 A phase I and pharmacokinetic (PK) s

✍ J. de Bono; G. Attard; R. Plummer; S. Pacey; C. Bale; L. Vidal; A. Greystoke; N. 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 138 KB

630 POSTER Results of a phase 2 study of

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 144 KB

P-460 Results of a phase 2 trial of HGS-

✍ Bonomi, P.; Greco, F.; Crawford, J.; Kelly, K.; Oh, Y.; Klein, J. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 150 KB

208 HGS-ETR1, a fully human monoclonal a

✍ S.J. Hotte; A.M. Oza; L.H. Le; M. MacLean; A. Iacobucci; A. Corey; N.L. Fox; H.W 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 151 KB